Methods and treatment of trauma adverse events with oxygen reduced blood
Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.
1. A method of reducing the risk of developing a hemorrhagic trauma adverse event in a hemorrhagic trauma subject in need thereof comprising administering stored oxygen reduced blood to a subject having hemorrhagic trauma, said stored oxygen reduced blood comprising a blood product having a reduced oxygen saturation level prior to storage for a storage period, wherein said hemorrhagic trauma adverse event is liver injury and said risk is reduced relative to a patient receiving conventionally stored blood.
2. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises increased levels of liver enzyme aspartate aminotransferase (AST) prior to said administering.
3. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises increased levels of liver enzyme alanine aminotransferase (ALT) prior to said administering.
4. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises decreased hematocrit prior to said administering.
5. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises an increased lactate level prior to said administering.
6. The method of claim 1 , wherein said stored oxygen reduced blood is depleted to an oxygen saturation of 20% or less prior to said storage period.
7. The method of claim 1 , wherein said stored oxygen reduced blood comprises an oxygen saturation of 20% or less during said storage period.
8. The method of claim 1 , wherein said oxygen reduced blood is also carbon dioxide reduced.
9. The method of claim 1 , wherein said storage period is up to 42 days.
10. The method of claim 2 , wherein said increased AST level is reduced by at least 5% after said administering relative to a patient receiving conventionally stored blood.
11. The method of claim 3 , wherein said increased ALT level is reduced by at least 5% after said administering relative to a patient receiving conventionally stored blood.
12. The method of claim 5 , wherein said increased lactate level is reduced to between 0.5 and 2.5 mmol/L after said administering.
13. A method of reducing the risk of developing liver damage in a hemorrhagic trauma subject in need thereof comprising administering stored oxygen reduced blood to a subject having hemorrhagic trauma, said stored oxygen reduced blood comprising a blood product having a reduced oxygen saturation level prior to storage for a storage period, wherein said hemorrhagic trauma subject has increased levels of aspartate aminotransferase (AST), increased levels of alanine aminotransferase (ALT), or both AST and ALT and said risk of liver damage is reduced relative to a patient receiving conventionally stored blood.
14. The method of claim 13 , wherein said increased AST level is reduced by at least 5% after said administering relative to a patient receiving conventionally stored blood.
15. The method of claim 13 , wherein said increased ALT level is reduced by at least 5% after said administering relative to a patient receiving conventionally stored blood.
16. The method of claim 13 , wherein said stored oxygen reduced blood is depleted to an oxygen saturation of 20% or less prior to said storage period.
17. The method of claim 13 , wherein said stored oxygen reduced blood comprises an oxygen saturation of 20% or less during said storage period.
18. The method of claim 13 , wherein said oxygen reduced blood is also carbon dioxide reduced.
19. The method of claim 14 , wherein said storage period is up to 42 days.
20. The method of claim 14 , wherein said increased AST level is reduced by at least 10% after said administering relative to a patient receiving conventionally stored blood.
21. The method of claim 15 , wherein said increased ALT level is reduced by at least 10% after said administering relative to a patient receiving conventionally stored blood.